Novavax traded at $10.29 this Monday March 9th, increasing $0.31 or 3.06 percent since the previous trading session. Looking back, over the last four weeks, Novavax gained 17.54 percent. Over the last 12 months, its price rose by 25.73 percent. Looking ahead, we forecast Novavax to be priced at 9.68 by the end of this quarter and at 8.83 in one year, according to Trading Economics global macro models projections and analysts expectations.
Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).